Israel’s Kamada (reported here previously) has signed a deal to supply Israel’s Health ministry with its plasma-based hyperimmune immunoglobulin (IgG) product. The product treats COVID-19 patients with pneumonia and is currently in Phase 1 & 2 trials in Israel. https://nocamels.com/2020/10/kamada-deal-supply-israel-health-ministry-covid-19-antibody/ … Continue reading →

Three of the first critical Covid-19 patients treated with the new IgG plasma-derived “passive vaccine” product developed by Israel’s Kamada and Hadassah Medical Center (reported here previously), have made a rapid recovery and have now been discharged from Hadassah hospital. … Continue reading →

Israel’s Kamada (reported here previously) has completed manufacturing the first batch of its plasma-derived Immunoglobulin G (IgG) product for Covid-19 patients. Initial vials of the antibody have been made available for compassionate use in Israel. https://www.calcalistech.com/ctech/articles/0,7340,L-3834010,00.html

Israeli biotech Kamada (see here) has partnered Italy’s Kedrion to develop a human plasma-derived Anti-SARs-COV-2 product. Kamada will use its proprietary IgG platform technology and Kedrion will provide plasma from donors who have recovered from the virus. https://www.kedrion.com/kedrion-and-kamada-announce-collaboration-anti-covid-19-igg-0

Israel’s Kamada is developing a treatment against the coronavirus derived from the blood-plasma of patients who have recovered from the disease and are in convalescence. Kamada says that the plasma is likely to contain antibodies that can be the basis … Continue reading →